Arkolith/Insider Trading/TALS/Form 4

Requadt Scott

Chief Executive Officer, DirectorTalaris Therapeutics, Inc. (TALS) · full profile →Form 4 · filed Feb 3, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 30, 2022Grant(A)4$0.87$3590K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2023Grant(A)320K—$0320K
Feb 1, 2023Grant(A)320K—$0320K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-006998) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML